Docality.com Logo
 
Dr. Charanjit  Sandhu  Md image

Dr. Charanjit Sandhu Md

7 Parkcenter Dr Suite 100
Sacramento CA 95825
916 694-4400
Medical School: Other - 1982
Accepts Medicare: No
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: Yes
License #: A52600
NPI: 1275500068
Taxonomy Codes:
207R00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Charanjit Sandhu is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99239 Description:Hospital discharge day Average Price:$311.00 Average Price Allowed
By Medicare:
$105.94
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$302.00 Average Price Allowed
By Medicare:
$102.23
HCPCS Code:99238 Description:Hospital discharge day Average Price:$217.00 Average Price Allowed
By Medicare:
$71.77
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$211.00 Average Price Allowed
By Medicare:
$71.36
HCPCS Code:99203 Description:Office/outpatient visit new Average Price:$144.71 Average Price Allowed
By Medicare:
$107.51
HCPCS Code:20610 Description:Drain/inject joint/bursa Average Price:$106.00 Average Price Allowed
By Medicare:
$71.15
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$137.93 Average Price Allowed
By Medicare:
$106.98
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$42.58 Average Price Allowed
By Medicare:
$19.76
HCPCS Code:17000 Description:Destruct premalg lesion Average Price:$105.89 Average Price Allowed
By Medicare:
$83.97
HCPCS Code:99211 Description:Office/outpatient visit est Average Price:$35.00 Average Price Allowed
By Medicare:
$20.65
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$85.79 Average Price Allowed
By Medicare:
$72.42
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$36.11 Average Price Allowed
By Medicare:
$25.42
HCPCS Code:Q2036 Description:Flulaval vacc, 3 yrs & >, im Average Price:$20.00 Average Price Allowed
By Medicare:
$9.82
HCPCS Code:90471 Description:Immunization admin Average Price:$32.56 Average Price Allowed
By Medicare:
$25.42
HCPCS Code:17003 Description:Destruct premalg les 2-14 Average Price:$13.44 Average Price Allowed
By Medicare:
$7.36
HCPCS Code:81002 Description:Urinalysis nonauto w/o scope Average Price:$8.44 Average Price Allowed
By Medicare:
$3.62
HCPCS Code:J3420 Description:Vitamin b12 injection Average Price:$5.00 Average Price Allowed
By Medicare:
$0.52
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$29.98 Average Price Allowed
By Medicare:
$25.68
HCPCS Code:J0696 Description:Ceftriaxone sodium injection Average Price:$5.00 Average Price Allowed
By Medicare:
$0.82
HCPCS Code:90732 Description:Pneumococcal vaccine Average Price:$67.69 Average Price Allowed
By Medicare:
$64.21
HCPCS Code:J3301 Description:Triamcinolone acet inj NOS Average Price:$5.00 Average Price Allowed
By Medicare:
$1.68
HCPCS Code:G0009 Description:Admin pneumococcal vaccine Average Price:$27.69 Average Price Allowed
By Medicare:
$25.37

HCPCS Code Definitions

99203
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.
96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
90471
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
20610
Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa)
99211
Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional. Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services.
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
17003
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); second through 14 lesions, each (List separately in addition to code for first lesion)
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
17000
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion
99238
Hospital discharge day management; 30 minutes or less
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99239
Hospital discharge day management; more than 30 minutes
G0009
Administration of pneumococcal vaccine
G0008
Administration of influenza virus vaccine
J0696
Injection, ceftriaxone sodium, per 250 mg
J3420
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
J3301
Injection, triamcinolone acetonide, not otherwise specified, 10 mg
Q2036
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1881681930
Cardiovascular Disease (Cardiology)
1,440
1134209000
Internal Medicine
699
1538186044
Ophthalmology
350
1437147923
Cardiac Surgery
293
1154342343
Nephrology
270
1992896286
Gastroenterology
238
1619952199
Internal Medicine
233
1629075718
Interventional Radiology
229
1801893193
Diagnostic Radiology
218
1528066164
Diagnostic Radiology
211
*These referrals represent the top 10 that Dr. Sandhu has made to other doctors

Publications

Evaluation of data-dependent versus targeted shotgun proteomic approaches for monitoring transcription factor expression in breast cancer. - Journal of proteome research
In breast cancer, there is a significant degree of molecular diversity among tumors. Multiple perturbations in signal transduction pathways impinge on transcriptional networks that in turn dictate malignant transformation and metastatic progression. Detailed knowledge of the sequence-specific transcription factors that become activated or repressed within a tumor and comparison of their relative levels of expression in cancer versus normal tissue should therefore provide insight into disease mechanisms, improving patient stratification and facilitating personalized treatment. While high-throughput tandem mass spectrometry methods for global proteome profiling have been developed, existing approaches have limited sensitivity and are often unable to detect low-abundance transcription factors in a complex biological specimen like a biopsy or tumor cell extract. To this end, we have undertaken a systematic comparative evaluation of three MS/MS methods for the ability to detect reference transcription factors spiked in known amounts into a cell-free breast cancer nuclear extract: Data-Dependent Acquisition (DDA), wherein precursor ion intensity dictates selection for fragmentation; Targeted Peptide Monitoring (TPM), a directed approach using successive isolation and fragmentation of predefined m/ z ratios; and Multiple Reaction Monitoring (MRM), in which specific precursor ion to product ion transitions are selectively monitored. Through a series of controlled, parallel benchmarking experiments, we have determined the relative figures-of-merit of each approach, and have established that prior knowledge of signature proteotypic peptides markedly improves overall detection sensitivity, reliability, and quantification.
Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. - Journal of proteome research
Protein expression becomes altered in breast epithelium during malignant transformation. Knowledge of these perturbations should provide insight into the molecular basis of breast cancer, as well as reveal possible new therapeutic targets. To this end, we have performed an extensive comparative proteomic survey of global protein expression patterns in proliferating MCF-7 breast cancer cells and normal human mammary epithelial cells using gel-free shotgun tandem mass spectrometry. Pathophysiological alterations associated with the malignant breast cancer phenotype were detected, including differences in the apparent levels of key regulators of the cell cycle, signal transduction, apoptosis, transcriptional regulation, and cell metabolism.
Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest. - Molecular and cellular biology
p27(Kip1) is an important effector of G(1) arrest by transforming growth factor beta (TGF-beta). Investigations in a human mammary epithelial cell (HMEC) model, including cells that are sensitive (184(S)) and resistant (184A1L5(R)) to G(1) arrest by TGF-beta, revealed aberrant p27 regulation in the resistant cells. Cyclin E1-cyclin-dependent kinase 2 (cdk2) and cyclin A-cdk2 activities were increased, and p27-associated kinase activity was detected in 184A1L5(R) cells. p27 from 184A1L5(R) cells was localized to both nucleus and cytoplasm, showed an altered profile of phosphoisoforms, and had a reduced ability to bind and inhibit cyclin E1-cdk2 in vitro when compared to p27 from the sensitive 184(S) cells. In proliferating 184A1L5(R) cells, more p27 was associated with cyclin D1-cdk4 complexes than in 184(S). While TGF-beta inhibited the formation of cyclin D1-cdk4-p27 complexes in 184(S) cells, it did not inhibit the assembly of cyclin D1-cdk4-p27 complexes in the resistant 184A1L5(R) cells. p27 phosphorylation changed during cell cycle progression, with cyclin E1-bound p27 in G(0) showing a different phosphorylation pattern from that of cyclin D1-bound p27 in mid-G(1). These data suggest a model in which TGF-beta modulates p27 phosphorylation from its cyclin D1-bound assembly phosphoform to an alternate form that binds tightly to inhibit cyclin E1-cdk2. Altered phosphorylation of p27 in the resistant 184A1L5(R) cells may favor the binding of p27 to cyclin D1-cdk4 and prevent its accumulation in cyclin E1-cdk2 in response to TGF-beta.

Map & Directions

7 Parkcenter Dr Suite 100 Sacramento, CA 95825
View Directions In Google Maps

Nearby Doctors

777 Campus Commons Rd Suite 120
Sacramento, CA 95825
916 298-8564
1870 Avondale Ave Suite #2
Sacramento, CA 95825
916 815-5990
650 Howe Ave #100
Sacramento, CA 95825
916 249-9337
2025 Morse Ave
Sacramento, CA 95825
916 735-5000
2025 Morse Ave
Sacramento, CA 95825
916 735-5000
730 Howe Ave Suite 200
Sacramento, CA 95825
916 679-9707
2025 Morse Avenue
Sacremento, CA 95825
916 734-4403
2025 Morse Ave
Sacramento, CA 95825
916 735-5000
2025 Morse Ave
Sacramento, CA 95825
916 735-5000
2025 Morse Ave
Sacramento, CA 95825
916 735-5000